Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

• Tipo: Artigo em Revista Científica Internacional
• Data: 2014

Autores

Fangueiro, JF (Autor) Outra; Andreani, T (Autor) Outra; Egea, MA (Autor) Outra; Garcia, ML (Autor) Outra; Souto, SB (Autor) Outra; Silva, AM (Autor) Outra; Souto, EB (Autor) Outra

Revista

Título: International Journal of Pharmaceutics

Vol. 461

Páginas: 64-73

ISSN: 0378-5173

Editora: Elsevier

Indexação

ISI Web of Knowledge - 108 Citações

Scopus - 119 Citações

Outras Informações

ID Authenticus: P-008-J7Z

DOI: 10.1016/j.ijpharm.2013.11.025

Abstract (EN): In the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5 wt% of CTAB.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 10